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Background/aim: Erythropoietin (EPO) has been proven recently to be a critical mediator in retinal neovascularization (RNV).
Previous studies have indicated that the use of recombinant human EPO (rEPO) is a high risk factor in the development of retinopathy
of prematurity. In this study, we aimed to investigate the effect of rEPO administration on RNV and its underlying mechanism in a
mouse model of oxygen-induced retinopathy (OIR).
Materials and methods: A murine model of OIR was used to generate RNV. After daily intraperitoneal injection of rEPO from
postnatal day 12 (P12), mice were euthanized at P17. Whole-mount retina staining was used to indicate the nonperfused area and
neovascularization tufts. Preretinal neovascular cells were calculated through hematoxylin and eosin staining. The expression levels of
vascular endothelial growth factor (VEGF) and inducible nitric oxide synthase (iNOS) were detected via western blot analysis.
Results: We found that injection of rEPO promoted the severity of RNV. The areas of neovascular tufts and preretinal neovascular cells
were increased after administration of rEPO. When mice were injected with rEPO, a dose-dependent upregulation in VEGF and iNOS
was observed.
Conclusion: The study indicates the proangiogenic role of EPO, suggesting that rEPO contributes to the pathogenesis of RNV.
Key words: Retinal neovascularization, oxygen-induced retinopathy, erythropoietin

1. Introduction
Retinopathy of prematurity (ROP) is a blinding eye
disorder that affects premature babies (1,2). In ROP, retinal
neovascularization (RNV) plays a central role and may
lead to blindness (1,3). The first phase of ROP is mainly
characterized by delayed vascular growth, and the second
phase is mainly present as RNV (4,5). The survival of lowbirth-weight infants is increasing due to the development
of neonatal care. However, the continuous demand for
supplementary oxygen probably increases the incidence of
ROP (6,7).
Erythropoietin (EPO), a hematopoietic glycoprotein
generated from the fetal liver and adult kidneys, is also
produced in low levels by central nervous system tissue.
EPO stimulates production of red blood cells. Recombinant
human EPO (rEPO) has been widely used in the treatment
of neonatal anemia (8,9). However, the relationship between
EPO and ROP still needs deeper investigation. EPO has
been reported as a retinal angiogenic factor in proliferative
diabetic retinopathy (PDR), as well as a risk factor for
developing ROP (10,11). In the vaso-obliterative phase,
supplementary EPO may protect the retina from vessel
* Correspondence: yiqiaoxing1111@hotmail.com

1642

loss, preventing oxygen-induced retinal angiogenesis. On
the other hand, suppression of EPO would be beneficial for
the inhibition of retinal pathological vessels in the second
phase (12). Intravitreal injection of small interference
RNA is effective in hindering the development of RNV
(12). Moreover, a recent study indicated that early EPO
administration did not raise the risk of ROP (13). A
clinical analysis found that rEPO was an independent
risk factor in the development of ROP (14). However, the
underlying mechanism by which exogenous EPO induces
angiogenesis is still uncertain.
In the present study, we investigate the effect of
rEPO treatment on the severity of retinal angiogenesis
and its possible mechanisms, which provides a better
understanding of RNV and a reasonable application of
rEPO.
2. Materials and methods
2.1. Animals
C57BL/6J mice were purchased from the Animal Center
of Wuhan University. About 10–16 mouse pups were used
per group, and both eyes were removed for experimental
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analysis. All experimental protocols related to animals
were approved by the Committee on the Ethics of Animal
Experiments of Wuhan University. This study was
implemented in accordance with the recommendations
in the Guide for the Care and Use Committee of Wuhan
University. All surgeries were performed under sodium
pentobarbital anesthesia, and every effort was made to
minimize suffering.
2.2. Oxygen-induced retinopathy
The mouse model of oxygen-induced retinopathy was
performed according to previous protocol (15). In brief,
postnatal mice at day 7 (P7) were exposed to 75% oxygen
conditions for 5 days. At P12, the mice were returned to
room air until P17 (Figure 1).
2.3. Intraperitoneal injection of rEPO
At P12, the mice were given daily intraperitoneal (IP)
injections of vehicle (saline) or 10 IU, 50 IU, or 100 IU
recombinant erythropoietin (rEPO, Roche Pharma Ltd.,
Basel, Switzerland). Mice were randomly divided into
the following groups: a room air (RA) group, an oxygeninduced retinopathy (OIR) group, an OIR treated with
saline (vehicle control) group, an OIR treated with 10 IU
rEPO group, an OIR treated with 50 IU rEPO group, and
an OIR treated with 100 IU rEPO group.
2.4. Retinal flat-mount fluorescent staining.
Retinal whole-mount staining was processed as previously
reported (16). At P17, eyes were enucleated and then
fixed in 4% paraformaldehyde (PFA) for 1 h at room
temperature. Retinas were isolated and incubated with
Griffonia simplicifolia isolectin B4 conjugated to Alexa
Fluor 594 (1:200; Invitrogen, Carlsbad, CA, USA) for 48
h at 4 °C. The retinas were then mounted onto slides with
antifading medium. Images were taken by fluorescent

microscope (BX63; Olympus, Tokyo, Japan). Adobe
Photoshop CS5 was used to quantify the area of RNV,
which was processed as previously described (17).
2.5. Hematoxylin and eosin (H&E) staining
After removal, eyeballs were fixed and embedded in
paraffin. Serial sections (6 µm) of eyes were cut sagittally
at 32-µm intervals. Only cross-sections through the optic
nerve were selected. Images were taken by light microscope
(BX63; Olympus, Tokyo, Japan). Preretinal neovascular
nuclei were distinguished from other structures and
counted via light microscopy.
2.6. Western blot analysis
Western blot was performed according to a standard
protocol (18). First, retinas were prepared for protein
extraction. Proteins were isolated by sodium dodecyl
sulfate–polyacrylamide gel electrophoresis (SDS-PAGE)
and then transferred to polyvinylidene fluoride (PVDF)
membranes. Membranes were incubated overnight at 4
°C with primary antibodies as follows: rabbit monoclonal
antibody against VEGF (1:500; Santa Cruz Biotechnology,
Santa Cruz, CA, USA), polyclonal rabbit antimouse iNOS
(1:500; Beijing Bioss Biotechnology Co. Ltd., Beijing,
China), GAPDH antibody (GAPDH rabbit mAb, 1:1000;
Cell Signaling Technology, Danvers, MA, USA). GAPDH
was set as the loading control. After being washed
thoroughly with TBS-T, the membranes were incubated
with HRP-conjugated goat antirabbit IgG (1:5000; Wuhan
Boster Biological Technology Ltd., Wuhan, China) at
room temperature for 90 min. The bands were visualized
with chemiluminescence and detected by photographic
film. Prestained marker (Fermentas, Baltimore, MD, USA)
was used to estimate the molecular weight of proteins. The
experiments were repeated 3 times.

Figure 1. Cartoon schematic of the murine model of OIR. Newborn mice are kept in room air from birth to postnatal day 7 (P7). At
P7, mice are exposed to 75% hyperoxygen, which suppresses normal retinal development and leads to significant vessel loss. Mice are
then back to room air at P12; hypoxic avascular area of retina triggers pathological neovascular response. RNV reaches its peak at P17,
which is visualized and quantified.
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2.7. Statistical analysis
All values are presented as the mean ± standard deviation
(SD). Group differences were compared by one-way
analysis of variance followed with the Bonferroni post hoc
test for multiple comparisons. P < 0.05 was considered as
statistically significant.
3. Results
3.1. Establishment of OIR model
At P17, retinal flat-mount fluorescence and H&E
staining were conducted to determine the successful
establishment of OIR. Whole-mount staining of isolectin
B4 revealed a clear central area of nonperfusion (Figure
2). Neovascular tufts were present at the junction between
the vascularized area and the nonperfused region, mainly
in the midperipheral area of the retina. However, no vasoobliteration area or pathological vessels were found in the
RA group. Consistently, H&E staining showed that many
preretinal neovascular cells emerged from the inner retinal
layer extending to the vitreous chamber (Figure 3). The
results proved that RNV was substantially induced after
hyperoxygen exposure.
3.2. Administration of rEPO promotes RNV in OIR
After daily administration of rEPO from P12 in OIR,
whole-mount staining of retinas and calculation of RNV
indicated that no significant difference was found in the
neovascular tuft area between the vehicle control (saline)
and 10 IU groups (Figure 4; 16.48% ± 3.075% vs. 17.33% ±
2.97%; t = 0.641; P > 0.05), while 50 IU and 100 IU rEPO

injections significantly aggregated the severity of RNV
compared to the saline group (Figure 4; 20.37% ± 1.678%
and 22.25% ± 3.705% vs. 16.48% ± 3.075%; t = 2.949 and
4.379, respectively; P < 0.05). The outcome indicated that
rEPO increased the neovascular tufts dose-dependently.
However, a low dose (10 IU) of rEPO did not significantly
promote the growth of aberrant vessels.
3.3. Injection of rEPO increased the number of preretinal
neovascular cells
H&E staining of sections and quantification of preretinal
neovascular cells showed that, after injection of rEPO, the
number of preretinal neovascular cells obviously increased
in the 50 IU and 100 IU groups compared with that from
the saline group (Figure 5; 51.30 ± 5.14 and 56.90 ± 7.85
vs. 38.90 ± 8.66; t = 3.759 and 5.457, respectively; P < 0.05).
However, no significant difference was found between the
saline group and the 10 IU rEPO group (Figure 5; 38.90 ±
8.66 vs. 47.40 ± 7.382; t = 2.577; P < 0.05). The outcome
also demonstrated that a low dose (10 IU) of rEPO did not
significantly increase the number of neovascular cells.
3.4. Effect of rEPO on the expression of VEGF and iNOS
Changes in the expression of proangiogenic proteins such
as VEGF and iNOS were evaluated via western blot analysis
(Figure 6). Compared with those in the vehicle control
group, protein levels of VEGF and iNOS were significantly
upregulated in the 100 IU rEPO group (P < 0.05). However,
no statistical significance was found when comparing the
expression of VEGF and iNOS between the saline group and
the 10 IU rEPO group or 50 IU rEPO group.

Figure 2. Flat-mount retinal fluorescent staining: a) RA group; b) OIR group. Vasculatures stained by isolectin B4 (red)
show the construction of retinal vessels. In the room air (RA) group, no vaso-obliteration (VO) area or neovascular tufts
were observed while large nonperfused zones (white irregular circle) and RNV (white arrows) were discovered in the
OIR group at P17 (magnification 40×; scale bar = 500 µm).
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Figure 3. H&E staining: a) RA group; b) OIR group. Black arrows indicate the preretinal neovascular cells in the OIR group.
However, no neovascular cells were observed through H&E staining in the RA group (magnification 200×; scale bar = 50 µm).

4. Discussion
EPO has been used in the treatment of neonatal anemia
(8,13,19). Many studies have shown the close relationship
between administration of rEPO and the development of
ROP (8,14). A recent metaanalysis found that late EPO
supplementation does not significantly reduce or increase
any fatal adverse outcomes; there is only the increased
risk of ROP (8). However, early injection of rEPO is not
associated with the risk of retinopathy in premature infants
(13,19). The development of ROP has been divided into
2 phases according to the alteration of vasculature. The
vessel attenuation in the first phase leads to the hypoxiainduced vasoproliferation in the second phase. Chen et
al. (20) indicated that EPO treatment in the first phase
protected the retina from vessel regression, eventually
preventing RNV.
EPO is known as an oxygen-regulated hormone
that promotes erythrogenesis (12). Endogenous EPO in
the retina is crucial for retinal angiogenesis (10,20). A
previous study showed that mRNA expression of EPO
is increased greatly in the second phase of retinopathy
(12). After intravitreal injection of small interference
RNA (siRNA), expressions of EPO as well as RNV are
significantly suppressed through RNA interference. This
result indicates that the silencing of EPO in the OIR retina
inhibits the RNV (12). Another work also found that
antibodies against EPO hindered RNV by reducing EPO
to the physiologic level (10). These findings are consistent
with the present study, which has shown that exogenous
EPO has a proangiogenic effect on promoting RNV. In
the OIR model, we administered the rEPO daily from P12
to P17, which is equal to the second phase of ROP. The
results suggested the proangiogenic effect of rEPO in the

process of RNV, which is consistent with a recent study
that demonstrated that the late use of rEPO increased the
risk of ROP (8).
Quantification of RNV via retinal flat-mount staining
and section H&E staining has been used extensively to
evaluate the establishment of OIR and the severity of RNV
(15–17). In the present study, injection of rEPO led to
an increase of RNV, significantly so in the 50 IU and 100
IU groups. Our results showed that a high dose of rEPO
significantly promotes the development of RNV in mice.
Despite the obvious demonstration of rEPO’s role as
a proangiogenic protein, the underlying mechanism by
which this works is a matter for speculation. We found that
a high dose of rEPO (100 IU) significantly upregulated
the expression of VEGF and iNOS. VEGF is a key and
well-known factor in the process of angiogenesis, which
stimulates endothelial cell activation and proliferation
(21–23). A previous study demonstrated a higher vitreous
level of EPO in stage 4 ROP, which was significantly
correlated with the level of VEGF in the vitreous chamber
of the eyes (24). Moreover, VEGF has been suggested to
mediate angiogenesis through erythropoiesis-stimulating
factors (25). The present investigation revealed that
treatment with 100 IU of rEPO exacerbated RNV via
increasing the level of VEGF expression, suggesting that
rEPO induced upregulation of VEGF, which contributed
to the pathogenesis of RNV.
Nitric oxide (NO) is synthesized by 3 kinds of NO
synthase, including neuronal nitric oxide synthases (nNOS),
endothelial nitric oxide synthases (eNOS), and inducible
nitric oxide synthase (iNOS). Nitric oxide is a critical
molecule that takes part in angiogenesis (26,27). iNOS is
expressed in the ischemic retina and has been proven to be
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Figure 4. Quantification of RNV after rEPO administration: a) saline group; b) 10 IU rEPO group; c) 50 IU rEPO group; d) 100 IU rEPO
group; e) quantification analysis of RNV. Data are presented as mean ± SD. Whole-mount staining showed that central ischemic area
and RNV tufts were present in all groups that were exposed to hyperoxygen at P12 and received administration of saline or a gradient
dose of rEPO (magnification 40×; scale bar = 500 µm). Significantly, 50 IU and 100 IU rEPO exacerbated development of RNV at P17
when compared to the saline group (n = 10; *P < 0.05, ***P < 0.001).
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Figure 5. Measurement of preretinal neovascular cell nuclei: a) saline group; b) 10 IU rEPO group; c) 50 IU rEPO group;
d) 100 IU rEPO group; e) quantification of preretinal neovascular cells. Data are presented as mean ± SD. H&E staining
indicated that neovessels extending to the vitreous chamber were present in every group (magnification 200×; scale bar
= 50 µm). High doses of rEPO (50 IU and 100 IU) significantly increased the number of preretinal neovascular cells at
P17 compared to the saline group (n = 10; *P < 0.05, ***P < 0.001).
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Figure 6. Effects of rEPO on retinal protein levels of VEGF and iNOS. The protein levels were normalized to GAPDH. Data are
presented as mean ± SD. Western blot analysis indicated that 100 IU rEPO injection significantly upregulated the protein levels
of VEGF and iNOS (*P < 0.05).

involved in tumor-induced angiogenesis and ischemic RNV
(28–30). Previous studies showed that inhibition of iNOS
significantly suppressed RNV in the OIR model (31,32). He
et al. suggested that iNOS mediates hypoxia inducible factor
1 alpha (HIF-1α) activation and VEGF upregulation in
RNV through the PI3K/Akt pathway (31). NO-dependent
pathways refer to a potential mechanism by which EPO
stimulates bone repair and angiogenesis (33). EPO was
attributed to an upregulation of iNOS, as previously reported
(34). We consistently found that 100 IU rEPO injection
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promoted RNV and increased expression of iNOS in the
OIR mouse model, indicating that rEPO aggregated RNV
by inducing the expression of iNOS and VEGF.
In conclusion, this investigation reveals that
administration of rEPO exacerbates RNV in a mouse
model of OIR, possibly via activation of VEGF and
upregulation of iNOS. The study not only indicates that
the dose and timing of rEPO treatment are important to
preterm infants, but also provides theoretical evidence for
restraint of rEPO-induced RNV clinically.
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